Dr Reddys Laboratories (RDY) Non-Current Deferred Tax Liability (2017 - 2026)

Dr Reddys Laboratories has reported Non-Current Deferred Tax Liability over the past 10 years, most recently at $170.3 million for Q1 2026.

  • For Q1 2026, Non-Current Deferred Tax Liability rose 4.53% year-over-year to $170.3 million; the TTM value through Mar 2026 reached $170.3 million, up 4.53%, while the annual FY2026 figure was $170.3 million, 3.21% up from the prior year.
  • Non-Current Deferred Tax Liability for Q1 2026 was $170.3 million at Dr Reddys Laboratories, up from $162.9 million in the prior quarter.
  • Over five years, Non-Current Deferred Tax Liability peaked at $170.3 million in Q1 2026 and troughed at $797944.4 in Q1 2022.
  • A 5-year average of $71.0 million and a median of $10.9 million in 2024 define the central range for Non-Current Deferred Tax Liability.
  • Biggest five-year swings in Non-Current Deferred Tax Liability: crashed 82.79% in 2022 and later surged 1388.43% in 2025.
  • Year by year, Non-Current Deferred Tax Liability stood at $797944.4 in 2022, then skyrocketed by 1169.93% to $10.1 million in 2023, then increased by 8.02% to $10.9 million in 2024, then surged by 1388.43% to $162.9 million in 2025, then rose by 4.53% to $170.3 million in 2026.
  • Business Quant data shows Non-Current Deferred Tax Liability for RDY at $170.3 million in Q1 2026, $162.9 million in Q1 2025, and $10.9 million in Q1 2024.